Elanco Animal Health Incorporated (5EA)
XFRA 
Summary
5EA Chart
Elanco Animal Health: New Products To Support Growth
I recommend a buy rating for Elanco Animal Health, driven by a strong new product cycle and robust clinic adoption. Zenrelia and Credelio Quattro are gaining significant market share, supporting double-digit revenue growth and margin expansion for ELAN. Befrena offers another growth lever, with early demand exceeding expectations, though near-term contribution is limited by supply constraints.
Elanco: Innovation Is Turning A Leveraged Portfolio Into A Share-Taking Platform
Elanco Animal Health is transitioning from a leveraged consolidator to an innovative competitor, with new products driving EBITDA growth and market share gains. ELAN's innovation portfolio, including Zenrelia, Credelio Quattro, and Befrena, is capturing share in dermatology and parasiticide markets, challenging Zoetis' key franchises. Margin expansion and deleveraging are underway, supported by the Ascend program and strong cash flow; net leverage is targeted below 3.0x by 2027.
Elanco Animal Health Q2 Earnings Call Highlights
Elanco Animal Health NYSE: ELAN reported second-quarter 2026 revenue of $1.368 billion, up 10% on a reported basis and 8% organically in constant currency, as demand for new pet-health products and strength in U.S. farm animal operations supported growth.
Elanco Animal Health Incorporated (5EA) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Elanco Animal Health Incorporated ever had a stock split?
Elanco Animal Health Incorporated Profile
| Specialty Retail Industry | Consumer Discretionary Sector | Jeffrey N. Simmons CEO | XFRA Exchange | 28414H103 CUSIP |
| US Country | 9,650 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Elanco Animal Health Incorporated is an animal health company founded in 1954 with its headquarters in Greenfield, Indiana. Specializing in the innovation, development, manufacturing, and marketing of products for pets and farm animals, Elanco aims to improve the health and productivity of those animals through a comprehensive range of products. The company distributes its offerings globally, catering to third-party distributors, veterinarians, and farm animal producers, which include beef and dairy farmers, as well as those involved in pork, poultry, and aquaculture operations.
Products and Services
- Pet Health Disease Prevention: Elanco provides a variety of parasiticide and vaccine products under brands such as Seresto, Advantage, Advantix, and Advocate. These products are designed to protect pets from common pests like worms, fleas, and ticks.
- Pet Health Therapeutics: The company offers products for pain, osteoarthritis, ear infections, cardiovascular issues, and dermatology symptoms in dogs and cats. Notable brands include Galliprant and Claro, which serve to enhance the well-being of pets and treat common health conditions.
- Poultry and Aquaculture Production: For the poultry and aquaculture sectors, Elanco markets vaccines, antibiotics, parasiticides, and other essential products. They also provide nutritional health products such as enzymes, probiotics, and prebiotics to support the overall health and productivity of animals in these industries.
- Ruminant and Swine Production: Elanco supports ruminant and swine producers with a vast array of products including vaccines, antibiotics, implants, and parasiticides. Noteworthy brands such as Rumensin and Baytril play a significant role in ensuring the health and efficiency of these farm animals. These products are integral in enhancing feed efficiency, preventing disease, and maintaining the health of livestock.
